Impact of combined mTOR and MEK inhibition in uveal melanoma is driven by tumor genotype.

Impact of combined mTOR and MEK inhibition in uveal melanoma is driven by tumor genotype.

Uveal melanomas possess activation of the mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K)/AKT/mammalian Target of Rapamycin (mTOR) pathways. MAPK activation occurs via somatic mutations in the heterotrimeric G protein subunits GNAQ and GNA11 for over 70% of tumors and le...

Full description

Bibliographic Details
Main Authors: Alan L Ho, Elgilda Musi, Grazia Ambrosini, Jayasree S Nair, Shyamprasad Deraje Vasudeva, Elisa de Stanchina, Gary K Schwartz
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2012-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3393714?pdf=render

Internet

http://europepmc.org/articles/PMC3393714?pdf=render

Similar Items